S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Spectrum Pharmaceuticals Stock Forecast, Price & News

-0.01 (-1.28%)
(As of 07/1/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
1.66 million shs
Average Volume
3.58 million shs
Market Capitalization
$138.59 million
P/E Ratio
Dividend Yield
Price Target

Spectrum Pharmaceuticals Stock Forecast (MarketRank)

Analyst Rating
Moderate Buy
2.75 Rating Score
679.6% Upside
$6.00 Price Target
Short Interest
12.10% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.94mentions of Spectrum Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$13.90 K Sold Last Quarter
Proj. Earnings Growth
From ($0.55) to ($0.10) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.25 out of 5 stars

Medical Sector

500th out of 1,429 stocks

Pharmaceutical Preparations Industry

210th out of 682 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive SPPI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spectrum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Spectrum Pharmaceuticals logo

About Spectrum Pharmaceuticals (NASDAQ:SPPI)

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Henderson, Nevada.

SPPI Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
$-158.63 million
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$0.29 per share


Free Float
Market Cap
$138.59 million

Social Links

Spectrum Pharmaceuticals Frequently Asked Questions

Should I buy or sell Spectrum Pharmaceuticals stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Spectrum Pharmaceuticals stock.
View analyst ratings for Spectrum Pharmaceuticals
or view top-rated stocks.

What is Spectrum Pharmaceuticals' stock price forecast for 2022?

4 analysts have issued twelve-month price objectives for Spectrum Pharmaceuticals' stock. Their SPPI stock forecasts range from $4.00 to $10.00. On average, they anticipate Spectrum Pharmaceuticals' share price to reach $6.00 in the next year. This suggests a possible upside of 679.6% from the stock's current price.
View analysts' price targets for Spectrum Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has Spectrum Pharmaceuticals' stock price performed in 2022?

Spectrum Pharmaceuticals' stock was trading at $1.27 on January 1st, 2022. Since then, SPPI shares have decreased by 39.4% and is now trading at $0.7696.
View the best growth stocks for 2022 here

When is Spectrum Pharmaceuticals' next earnings date?

Spectrum Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Spectrum Pharmaceuticals

How were Spectrum Pharmaceuticals' earnings last quarter?

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) announced its earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.21) earnings per share for the quarter, topping analysts' consensus estimates of ($0.28) by $0.07. During the same period in the prior year, the business posted ($0.37) earnings per share.
View Spectrum Pharmaceuticals' earnings history

Who are Spectrum Pharmaceuticals' key executives?

Spectrum Pharmaceuticals' management team includes the following people:
  • Mr. Thomas J. Riga, Pres, CEO & Director (Age 47, Pay $1.02M) (LinkedIn Profile)
  • Ms. Nora E. Brennan, Exec. VP & Chief Financial Officer (Age 53, Pay $54.17k)
  • Mr. Keith M. McGahan J.D., L.L.M., Exec. VP, Chief Legal Officer & Corp. Sec. (Age 46, Pay $851.73k) (LinkedIn Profile)
  • Dr. Francois J. Lebel FRCPC, M.D., Exec. VP & Chief Medical Officer (Age 70, Pay $917.96k)
  • Mr. Bimal R. Shah, VP of Corp. & Bus. Devel.
  • Dr. Lyndah K. Dreiling M.B.A., M.D., Sr. VP of Clinical Devel.

What is Joseph Turgeon's approval rating as Spectrum Pharmaceuticals' CEO?

2 employees have rated Spectrum Pharmaceuticals CEO Joseph Turgeon on Glassdoor.com. Joseph Turgeon has an approval rating of 47% among Spectrum Pharmaceuticals' employees. This puts Joseph Turgeon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Spectrum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spectrum Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Verastem (VSTM), Exelixis (EXEL), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), OPKO Health (OPK), Bausch Health Companies (BHC), Sorrento Therapeutics (SRNE) and Zynerba Pharmaceuticals (ZYNE).

What is Spectrum Pharmaceuticals' stock symbol?

Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."

How do I buy shares of Spectrum Pharmaceuticals?

Shares of SPPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Spectrum Pharmaceuticals' stock price today?

One share of SPPI stock can currently be purchased for approximately $0.77.

How much money does Spectrum Pharmaceuticals make?

Spectrum Pharmaceuticals (NASDAQ:SPPI) has a market capitalization of $138.59 million. The biotechnology company earns $-158.63 million in net income (profit) each year or ($0.88) on an earnings per share basis.

How many employees does Spectrum Pharmaceuticals have?

Spectrum Pharmaceuticals employs 163 workers across the globe.

When was Spectrum Pharmaceuticals founded?

Spectrum Pharmaceuticals was founded in 2002.

How can I contact Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The official website for Spectrum Pharmaceuticals is www.sppirx.com. The biotechnology company can be reached via phone at (702) 835-6300, via email at [email protected], or via fax at 702-260-7405.

This page (NASDAQ:SPPI) was last updated on 7/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.